Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection

Inclusion Criteria: * Patients must have squamous cell carcinoma with a depth invasion \> 1 mm * Patients must have T1 or T2 tumors (International Federation of Gynecology and Obstetrics\[FIGO\] staging), \< 4 cm, not encroaching in urethra, vagina, or anus with clinically negative inguinofemoral lymph nodes * Localization and size of the tumor are such that peri-lesional injection of the tracers at three or four sites is possible * Preoperative imaging do not show enlarged (\< 1.5 cm) suspicious nodes * Patients must sign informed consent Exclusion Criteria: * Inoperable tumors with diameter \> 4 cm * Patients with inguinofemoral lymph nodes, at palpation clinically suspect for metastases, at radiology enlarged (\> 1.5 cm) suspicious groin nodes and with cytologically proven inguinofemoral lymph node metastases * Patients with multifocal tumors * Patients who are currently on an investigational drug for the treatment of vulvar cancer are excluded from participation in this trial